#FDAApproval #ObesityManagement #GLP1 #ClinicalPharmacology #NewDrugApproval #WeightManagement #HealthcareInnovation #MedicalEducation #Orforglipron #Foundayo To view or add a comment, sign in Just as employers start to get their arms around GLP-1 costs the next wave is already hereand its more powerful
Microdosing allows for appetite awareness rather than appetite elimination
In this context, retatrutide provides a useful model for studying how incretin and glucagon pathway integration shapes adipose tissue responses, rather than isolating a single receptor axis
References Kim W, Egan JM
Beyond those concerns, experts point to several other potential downsides: Limited evidence for people without obesity or related conditions
4,18 Data suggest that dulaglutide and liraglutide may be associated with higher rates of nausea, vomiting, and constipation compared with semaglutide, whereas pharmacovigilance analyses indicate that semaglutide carries the greatest signal strength for these AEs